Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
AstraZeneca
Express Scripts
McKesson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,857,802

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,857,802 protect, and when does it expire?

Patent 7,857,802 protects NAROPIN and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.

Summary for Patent: 7,857,802
Title:Connector for medical liquid-containing packages and medical liquid-containing packages
Abstract: The invention relates to a connector for medical liquid-containing packages, in particular to infusion or transfusion bags comprising a connection element (1) provided with a channel-shaped opening (1c) in which a self-sealing membrane (8) is arranged. A breakable part (17) which is connected to the connection piece closes the channel-shaped opening. Above the membrane (8), said connection element is embodied in the form a connection piece (13) comprising an internal cone (14) and external thread (15), the membrane (8) being sealed for receiving a syringe cone shaft. The inventive connector makes it possible to inject an active substance by means of a conventional Luer lock syringe devoid of an injection cannula (needle).
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg V.D.H., DE)
Application Number:10/575,690
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 7,857,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No   Start Trial   Start Trial Y   Start Trial
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 AP RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,857,802

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 48 016Oct 15, 2003
PCT Information
PCT FiledOctober 15, 2004PCT Application Number:PCT/EP2004/011603
PCT Publication Date:April 28, 2005PCT Publication Number: WO2005/037362

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Colorcon
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.